Class summary at a glance.

Every drug in the Cephalosporin Antibacterial class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 13tracked in Part D
CY24 Part D spend: $182.3Mcombined across class
Total Rx claims: 6.1M4.7M unique beneficiaries
Generic mfrs (active): 51across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Cefdinir

3.5M Part D claims (CY24) · 2.9M beneficiaries · First FDA approval: 2006-05-30

6 generic mfrs 0 plans require PA

Low NADAC$0.104

→

Avg plan cost$0.244

Part D spend $54.7M 2× spread, current vs floor

Class share

30%

of class CY24 spend

View profile →

Cefpodoxime Proxetil

854K Part D claims (CY24) · 717K beneficiaries · First FDA approval: 2007-06-08

4 generic mfrs 0 plans require PA

Low NADAC$1.06

→

Avg plan cost$1.25

Part D spend $40.2M 1× spread, current vs floor

Class share

22%

of class CY24 spend

View profile →

Ceftriaxone

Brand: Ceftriaxone · 533K Part D claims (CY24) · 246K beneficiaries · First FDA approval: 2005-04-20

11 generic mfrs 0 plans require PA

Low NADAC$0.862

→

Avg plan cost$1.90

Part D spend $34.1M 2× spread, current vs floor

Class share

19%

of class CY24 spend

View profile →

Cefepime

Brand: CEFEPIME HYDROCHLORIDE AND DEXTROSE · 150K Part D claims (CY24) · 51K beneficiaries · First FDA approval: 2008-05-01

5 generic mfrs 0 plans require PA Discontinued

Low NADAC$3.73

→

Avg plan cost$3.73

Part D spend $27.5M 1× spread, current vs floor

Class share

15%

of class CY24 spend

View profile →

Cefadroxil

836K Part D claims (CY24) · 656K beneficiaries · First FDA approval: 2007-01-25

Brand-only (no generics) 0 plans require PA

Low NADAC$0.193

→

Avg plan cost$0.422

Part D spend $11.3M 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Cefazolin

Brand: CEFAZOLIN · 122K Part D claims (CY24) · 31K beneficiaries · First FDA approval: 1988-12-09

5 generic mfrs 2 plans require PA

Low NADAC$0.987

→

Avg plan cost$0.987

Part D spend $6.5M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Cefixime

27K Part D claims (CY24) · 22K beneficiaries · First FDA approval: 2015-04-14

5 generic mfrs 0 plans require PA

Low NADAC$2.25

→

Avg plan cost$7.53

Part D spend $2.8M 3× spread, current vs floor

Class share

of class CY24 spend

View profile →

Ceftazidime

Brand: TAZICEF · 25K Part D claims (CY24) · 9K beneficiaries · First FDA approval: 2005-11-02

2 generic mfrs 160 plans require PA Discontinued

Low NADAC$3.70

→

Avg plan cost$3.70

Part D spend $2.6M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Cefprozil

38K Part D claims (CY24) · 32K beneficiaries · First FDA approval: 2005-12-01

5 generic mfrs 0 plans require PA

Low NADAC$0.094

→

Avg plan cost$0.398

Part D spend $1.1M 4× spread, current vs floor

Class share

of class CY24 spend

View profile →

Cefaclor

14K Part D claims (CY24) · 8K beneficiaries · First FDA approval: 2002-09-26

2 generic mfrs 0 plans require PA

Low NADAC$0.874

→

Avg plan cost$1.06

Part D spend $825749 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Cefoxitin

Brand: Cefoxitin · 3K Part D claims (CY24) · 517 beneficiaries · First FDA approval: 2006-03-10

4 generic mfrs 99 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $591065

Class share

of class CY24 spend

View profile →

Cefuroxime

112 Part D claims (CY24) · 66 beneficiaries · First FDA approval: 2004-01-09

2 generic mfrs 66 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $7527

Class share

of class CY24 spend

View profile →

Cefotetan

Brand: Cefotan · — Part D claims (CY24) · First FDA approval: 2011-10-26

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.